Table 5 Viruses identified at baseline in trial participants
I-C | Placebo | |
|---|---|---|
Total number of patients tested (N) | 98 | 97 |
Number of virus positive patientsa, b (N, %) | 53 (54.1) | 54 (55.7) |
Influenza Type A | 1 (1.0) | 2 (2.1) |
Picornavirus (including HRV and HEV) | 30 (30.6) | 28 (29.3) |
Positive qualitative picornavirus assay | 26 (26.5) | 26 (26.8) |
Positive qualitative enterovirus assay | 2 (2.0) | 0 (0.0) |
Positive resultc on panenterhino/Ge/08 assay | 27 (27.6) | 28 (28.9) |
Quantifiable result on panenterhino/Ge/08 assay | 22 (22.4) | 24 (24.7) |
Human metapneumovirus | 0 (0.0) | 1 (1.0) |
Coronavirus | 23 (22.4) | 19 (19.6) |
Coronavirus 229E | 1 (1.0) | 2 (2.0) |
Coronavirus HKU1 | 1 (1.0) | 2 (2.1) |
Coronavirus NL63 | 9 (9.2) | 4 (4.1) |
Coronavirus OC43 | 12 (12.2) | 11 (11.3) |
Adenovirus | 0 (0.0) | 2 (2.1) |
Respiratory syncytial virus | 0 (0.0) | 1 (1.0) |
Parainfluenza | 5 (5.1) | 5 (5.2) |
Type 1 | 3 (3.1) | 0 (0.0) |
Type 2 | 1 (1.0) | 1 (1.0) |
Type 4 | 1 (1.0) | 4 (4.1) |